GA GENOTYPE OF THE ARG280HIS POLYMORPHISM ON
THE XRCC1 GENE: GENETIC SUSCEPTIBILITY GENOTYPE
IN DIFFERENTIATED THYROID CARCINOMAS?
Kirnap NG1,*, Tutuncu NB1,2, Yalcin Y2, Cebi HPB2, Tutuncu T2,3, Nar A1, Verdi H2, Atac FB2
*Corresponding Author: Nazlı G. Kirnap, M.D., Department of Endocrinology and Metabolism,
Başkent University Faculty of Medicine, Taskent Caddesi No. 77, Bahcelievler, 06490, Ankara, Turkey.
Tel.: +90-(0)312-203-6868. Fax: +90-(0)312-304-2700. E-mail: kirnapnazli@hotmail.com
page: 73
|
|
RESULTS
The baseline characteristics [age, sex, body mass
index (BMI), family history of thyroid cancer, presence of
Hashimoto’s thyroiditis, smoking status, thyroid stimulating
hormone (TSH) levels of both case and control groups]
are shown in Table 1. None of the patients enrolled in our
study had radiation exposure to the neck.
There was no significant difference in terms of BMI
between DTC and the healthy control group (p = 0.056).
The genotype frequencies of the three XRCC1 polymorphisms
(Arg194Trp, Arg280His, and Arg399Gln) in all
cases are given in Table 2. Genotype frequency of GA in
XRCC1 Arg280His polymorphism in the DTC group was
significantly higher than the BTN group (p <0.001) and
healthy control group (p <0.0001). Genotype frequency of
AA in XRCC1 Arg280His polymorphism was significantly
higher in the BTN group (65.0%) and highest in the healthy
control group (96.8%). The genotype frequency of AA
in XRCC1 Arg280His polymorphism was the lowest in
the DTC group (35.5%). The difference was statistically
significant (p <0.001) (Table 2; Figure 1).
In XRCC1 Arg194Trp polymorphism, genotype frequency
of CC was high in all three groups. However, the
genotype frequency of CT in XRCC1 Arg194Trp polymor- phism was less in all groups (2.2, 3.0 and 10.8%, respectively).
Moreover, the CT genotype was significantly more
common in the healthy control group when compared to
DTC and BTN groups (p = 0.001 and p = 0.032, respectively)
[Table 2; Figure 1(b)]. The distribution of genotype
frequencies in the XRCC1 Arg399Gln polymorphism were
similar in all three groups (p = 0.064).
Distributions of the three XRCC1 genotypes were
similar among obese, overweight and normal-weight individuals.
Furthermore, the coexistence of obesity and any
of the three genotypes of XRCC1 were not correlated with
the presence of thyroid cancer.
The highest frequency of Hashimoto’s thyroiditis was
encountered in the BTN group (25.0%), which was statistically
significant (p = 0.004). The coexistence of Hashimoto’s
thyroiditis and any of the XRCC1 genotypes was not found
to be correlated with the presence of thyroid cancer.
The frequency of those with a family history of thyroid
cancer was 7.9% (n = 18) in the DTC group and 1.0%
(n = 1) in the BTN group. The difference was statistically significant (p = 0.014). There was no case with a family
history of thyroid cancer in the healthy control group,
which caused a statistically significant difference among
the groups (p = 0.005).
Of the cases with XRCC1 Arg280His polymorphism
among those with a family history of thyroid cancer, 78.9%
had the GA genotype and 21.1% had the AA genotype, but
none had the GG genotype (p = 0.004). There was no significant
difference in terms of the distribution of Arg399Gln
and Arg194Trp polymorphisms of XRCC1 between those
with and without a family history of thyroid cancer (p =
0.704, p = 0.346, respectively) (Table 3). Among the DTC
cases, regarding the histological type of thyroid cancer,
there was no difference in the frequency of the three genotypes
of XRCC1 (Arg280His, Arg194Trp, Arg399Gln) in
those with papillary and follicular thyroid cancer.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
